Medical Marijuana Inc (OTCMKTS:MJNA) is a Company of Firsts® and dilution. MJNA is a cannabis and industrial hemp company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc.
According to their filings MJNA says it expects to continue to generate significant revenues from our core competencies. The demand for its products continues to increase, with the Brightfield Group recently reporting that the global demand for hemp-derived CBD products is expected to reach $22 billion by 2022, presenting a large business opportunity for the Company’s CBD-based products both within and outside of the U.S.
Medical Marijuana Inc. has developed a global portfolio of hemp-derived nutraceutical wellness brands, led by its subsidiaries, Kannaway.® and HempMeds.® Through its subsidiaries, Medical Marijuana Inc. offers products in diverse, high impact consumer categories such as digestibles, topicals, personal care, pet foods, and more. Medical Marijuana, Inc. brands are known as industry leading in safety and effectiveness — selling in over 30 countries — and have been featured by outlets such as GQ, women’s health, Vogue, and countless more. Second Initiative – Product Innovation & Supply
MJNA has established the world’s first supply chain of industrial hemp-derived cannabidiol, or CBD and now distributes and sells in the United States, throughout Europe, Latin America and in Japan. Medical Marijuana, Inc. became the first CBD based company to have its products listed in the Prescribers’ Digital Reference (PDR). The company is focused on further investment in vertical integration and manufacturing capacity that will enable further product innovation in the non-psychoactive nutraceutical space.
To Find out the inside Scoop on MJNA Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On October 29 MJNA reported its subsidiary Kannaway® has officially entered the U.S. cannabinol (CBN) market with the release of two new CBN isolate products. Not to be confused with cannabidiol (CBD), which has gained significant popularity over the past few years, CBN is another non-psychoactive cannabinoid found in the cannabis plant. Like the Company’s full-spectrum CBD products, Kannaway®’s CBN products are derived from all-natural hemp.
“We’re very excited to become one of the first major hemp-derived product producers to offer CBN,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “It is being researched in several different studies, including a 300 person study just announced on Oct. 28, for its potential sedation and sleep effects.”
This new product line includes:
Kannaway® Pure CBN Liquid: Isolated CBN is combined with sustainably sourced medium-chain triglyceride (MCT) oil, providing an abundant source of essential fatty acids that help to enhance bioavailability naturally. Offered in a 1-ounce bottle with a convenient dropper, each product delivers roughly 30 servings of 10 mg of CBN each.
Kannaway® Pure CBN Gel Capsules: Isolated CBN and MCT oil are also combined, but are presented in a convenient gel capsule form. They come in a 30-pack, with each gel capsule containing 20 mg of pure CBN.
“Though it may be too soon to predict the growth potential for the CBN market, analysts at the Nutrition Business Journal predict that the sleep supplement market will grow 30.1% this year,” said Kannaway CEO Blake Schroeder. “We intend to continue to stay up-to-date with the most recent discoveries in cannabinoid research and offer our customers the latest, most popular ingredients available in sleep science and other categories.”
$mjna woke up
— New York Nurse (@DinaDianaRN) November 6, 2020
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $53 million market valuation MJNA has $4.6 million in the treasury and just did $10.9 in the first quarter of 2020. g. These are huge numbers for the OTCBB. MJNA carries significant debt on the books and note holders continue to be a serious drag on the share price. MJNA also has been pink for a long, long time and has yet to get their filings in order or up list to the OTCBB. This continues to be a big problem for the Company. But MJNA is one pot stock to watch when the sector heats up; they are masters at selling the sizzle on the pot sector as well as getting themselves featured by mainstream media including Dateline NBC, The History Channel, BuzzFeed, Forbes, The Street, TMZ, Benzinga, Leafly, Chicago Tribune, Shape Magazine, Medium, Bustle, Vice and more. There is huge demand for MJNA and the stock regularly tops $500k in dollar volume per day. We will be updating on MJNA when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MJNA.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in MJNA either long or short and we have not been compensated for this article.